ICD-11 code 1C1E.2 refers to late lesions of Pinta, a disease caused by the bacterium Treponema carateum. Pinta is a non-venereal treponemal infection that primarily affects the skin, manifesting as pigmented patches or macules.
Late lesions of Pinta typically occur months to years after the initial infection and are characterized by hyperpigmentation, scaly plaques, and sometimes hair loss in the affected areas. The disease is usually non-symptomatic and does not cause systemic complications.
Pinta is endemic to certain regions of Central and South America, particularly rural areas with poor hygiene and limited access to healthcare. Early diagnosis and treatment with antibiotics such as penicillin are effective in curing Pinta and preventing the progression to late lesions.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The equivalent SNOMED CT code for ICD-11 code 1C1E.2, which pertains to late lesions of pinta, is 239640000. SNOMED CT, a comprehensive clinical terminology system used internationally, provides a standardized way of representing clinical information across healthcare settings. This unified coding system aids in interoperability and information exchange between different healthcare systems.
Pinta is a non-venereal treponematosis caused by Treponema carateum bacteria, primarily affecting skin and mucous membranes. Late lesions of pinta refer to the skin manifestations that appear in the later stages of the disease. By assigning the appropriate SNOMED CT code, healthcare providers can accurately document and share patient information related to late pinta lesions. This standardized coding system ensures consistency in reporting and analyzing epidemiological data for public health purposes.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Late lesions of pinta, designated as 1C1E.2, manifest in several distinct symptoms. One common characteristic is the appearance of hyperpigmented, atrophic macules on the skin. These macules are typically found on the trunk, extremities, and face of affected individuals.
At times, late lesions of pinta can present with a gray or blue hue, contributing to their distinctive appearance. Another symptom of 1C1E.2 is the presence of hypopigmented patches on the skin, which can vary in size and shape. These patches may be asymptomatic or associated with mild pruritus.
In some instances, late lesions of pinta can lead to the development of hyperkeratotic plaques on the skin. These plaques may be accompanied by scaling, itching, and discomfort. Additionally, individuals with 1C1E.2 may experience changes in pigmentation, with some areas of the skin becoming lighter or darker than surrounding skin.
🩺 Diagnosis
Diagnosis of 1C1E.2, commonly known as late lesions of pinta, typically involves a thorough physical examination of the patient. Healthcare providers will carefully inspect the skin for characteristic signs of the disease, such as hyperpigmented, scaly, and dry patches commonly found on the face, arms, legs, and genital regions.
In addition to a physical examination, a clinical history is essential for accurately diagnosing late lesions of pinta. Healthcare providers will inquire about the patient’s symptoms, the duration of the skin lesions, any previous treatments attempted, and any recent travel to endemic regions where pinta is prevalent.
Laboratory tests may also be conducted to confirm the diagnosis of 1C1E.2. These tests may include skin scraping or biopsy to examine the affected skin under a microscope for the presence of Treponema carateum, the bacteria responsible for causing pinta. Additionally, serological tests may be performed to detect antibodies specific to Treponema carateum in the patient’s blood, further confirming the diagnosis of late lesions of pinta.
💊 Treatment & Recovery
Treatment for late lesions of pinta, classified as 1C1E.2, typically involves the administration of antibiotics such as benzathine penicillin or other penicillin derivatives. These medications are effective in targeting the bacterium that causes pinta, Treponema carateum, and helping to eliminate the infection from the body. In some cases, a course of antibiotics may need to be repeated to ensure complete eradication of the bacteria.
Additionally, supportive care may be provided to help manage symptoms such as itching, pain, or skin changes associated with the late lesions of pinta. This may include the use of topical corticosteroids to reduce inflammation and discomfort, as well as regular monitoring of the affected skin for signs of improvement or worsening.
Recovery from late lesions of pinta can vary depending on the individual’s response to treatment and the extent of the infection. In some cases, patients may experience rapid resolution of symptoms and complete healing with appropriate antibiotic therapy. However, in more severe cases or when treatment is delayed, scarring or pigment changes may remain after the infection has cleared. Regular follow-up appointments with a healthcare provider may be necessary to monitor the progress of recovery and address any lingering concerns.
🌎 Prevalence & Risk
In the United States, 1C1E.2 (Late lesions of pinta) is extremely rare and virtually non-existent. The disease is more commonly found in tropical and subtropical regions where it is endemic, such as Central and South America, the Caribbean, Africa, and Southeast Asia. Due to the lack of suitable environmental conditions and limited exposure to the causative organism, cases of pinta, especially in its late stages, are seldom seen in the United States.
In Europe, cases of 1C1E.2 (Late lesions of pinta) are extremely rare and sporadic. The disease is typically not endemic to Europe and is more commonly found in tropical regions. European countries have established strict control measures to prevent the spread of pinta, as well as other neglected tropical diseases. As a result, the prevalence of late lesions of pinta in Europe is extremely low.
In Asia, 1C1E.2 (Late lesions of pinta) is more prevalent in certain regions where the disease is endemic, such as parts of Southeast Asia and the Pacific Islands. These areas have a higher incidence of pinta due to favorable environmental conditions and limited access to healthcare services. However, the overall prevalence of late lesions of pinta in Asia is still relatively low compared to other neglected tropical diseases.
In Africa, 1C1E.2 (Late lesions of pinta) is more commonly seen in certain regions where the disease is endemic, particularly in sub-Saharan Africa. The prevalence of late lesions of pinta in Africa is higher compared to other continents due to factors such as poverty, limited access to healthcare, and inadequate sanitation. Efforts to control and eliminate pinta in Africa have been ongoing, but the disease continues to pose a challenge in certain areas.
😷 Prevention
To prevent 1C1E.2 (Late lesions of pinta), effective measures can be taken to avoid contracting the related diseases of pinta, such as timely diagnosis and treatment.
Education and awareness programs focusing on the transmission and symptoms of pinta can help individuals recognize the early signs of the disease and seek medical attention promptly. Additionally, promoting personal hygiene practices, such as regular handwashing and avoiding close contact with infected individuals, can reduce the risk of contracting pinta.
Furthermore, implementing community-wide strategies, such as mass treatment campaigns and vector control measures, can help eliminate the causative agent of pinta and prevent its transmission. Collaboration between healthcare providers, public health agencies, and communities is essential in developing comprehensive prevention strategies to combat 1C1E.2 (Late lesions of pinta) and reduce its burden on affected populations.
🦠 Similar Diseases
One disease similar to 1C1E.2 (Late lesions of pinta) is secondary syphilis, coded as A51. Secondary syphilis presents with a wide range of symptoms, including rash, mucous membrane lesions, and generalized lymphadenopathy. Like late lesions of pinta, secondary syphilis can manifest with skin lesions that can be mistaken for other dermatological conditions.
Another disease similar to late lesions of pinta is lichen planus, coded as Lichen Planus. Lichen planus is a chronic inflammatory condition that commonly affects the skin, mucous membranes, and nails. Skin lesions in lichen planus can be reddish-purple in color and have distinct patterns. While lichen planus is not infectious like pinta, its skin lesions may be confused with those of late lesions of pinta.
Furthermore, cutaneous sarcoidosis (D86.8) shares similarities with late lesions of pinta in terms of skin manifestation. Cutaneous sarcoidosis is a multisystem inflammatory disorder that can present with skin lesions, often characterized by non-caseating granulomas. These granulomas can lead to the development of nodules, plaques, and papules on the skin, resembling the late lesions seen in pinta. The differential diagnosis of late lesions of pinta may include cutaneous sarcoidosis due to their overlapping skin manifestations.